International Biotechnology Trust’s Supernus Pharmaceuticals SUPN Stock Holding History

International Biotechnology Trust’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$11.8M	Sell	426,500 -97,000	-19%	-$2.95M	3.96%	6
2023 Q2	$15.7M	Buy	523,500 +100,000	+24%	+$3.5M	4.79%	5
2023 Q1	$15.3M	Buy	423,500 +40,000	+10%	+$1.54M	4.28%	6
2022 Q4	$13.7M	Buy	383,500 +86,000	+29%	+$2.99M	4.22%	7
2022 Q3	$10.1M	Buy	297,500 +288,896	+3,358%	+$9.4M	3.23%	10
2022 Q2	$298K	Sell	8,604 -288,896	-97%	-$8.27M	3.1%	10
2022 Q1	$17.5M	Hold	297,500	–	–	3.94%	9
2021 Q4	$8.68M	Hold	297,500	–	–	1.93%	20
2021 Q3	$7.93M	Buy	297,500 +95,064	+47%	+$2.55M	1.91%	18
2021 Q2	$6.23M	Buy	+202,436	New	+$6.21M	1.65%	20
2020 Q1	–	Sell	-19,953	Closed	-$473K	–	64
2019 Q4	$473K	Hold	19,953	–	–	0.17%	57
2019 Q3	$548K	Hold	19,953	–	–	0.25%	51
2019 Q2	$659K	Sell	19,953 -70,000	-78%	-$2.4M	0.24%	60
2019 Q1	$3.15M	Buy	89,953 +69,000	+329%	+$2.57M	1.16%	30
2018 Q4	$547K	Hold	20,953	–	–	0.34%	40
2018 Q3	$809K	Hold	20,953	–	–	0.38%	44
2018 Q2	$1.25M	Hold	20,953	–	–	0.48%	42
2018 Q1	$959K	Hold	20,953	–	–	0.37%	54
2017 Q4	$834K	Hold	20,953	–	–	0.29%	58
2017 Q3	$838K	Hold	20,953	–	–	0.33%	50
2017 Q2	$902K	Sell	20,953 -179,047	-90%	-$6.37M	0.34%	53
2017 Q1	$6.25M	Buy	+200,000	New	+$5.36M	2.39%	13

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

International Biotechnology Trust's SUPN Position: Q3 2023 in Review

International Biotechnology Trust reduced its Supernus Pharmaceuticals (SUPN) stake by 19% in Q3 2023, selling an estimated $2.95M and leaving 426,500 shares worth $11.8M. The position accounts for 3.96% of the portfolio, ranked #6.

International Biotechnology Trust first reported a position in SUPN in Q1 2017 and has held it in 22 quarters since. The position peaked at $17.5M in Q1 2022. 238 funds tracked by Wall St. Rank hold SUPN as of Q3 2023.

International Biotechnology Trust held 426,500 shares of Supernus Pharmaceuticals worth $11.8M as of Q3 2023.
International Biotechnology Trust sold 97,000 Supernus Pharmaceuticals shares in Q3 2023, an estimated $2.95M.
Supernus Pharmaceuticals made up 3.96% of International Biotechnology Trust's portfolio in Q3 2023, its #6 holding.
International Biotechnology Trust first reported a position in Supernus Pharmaceuticals in Q1 2017 and has held it in 22 quarters since.
International Biotechnology Trust's Supernus Pharmaceuticals position peaked at $17.5M in Q1 2022.
238 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2023.

Based on International Biotechnology Trust's 13F filing for Q3 2023, filed 14 Nov 2023.